Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators

Circulation

Volumn 101, Issue 3, 2000, Pages 235-238

  Pasceri, Vincenzo ^a,c   Wu, Henry D ^a   Willerson, James T ^a,c   Yeh, Edward T H ^a,b,c  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Atherosclerosis; Cell adhesion molecules; Receptors

Indexed keywords

APOLIPOPROTEIN E; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

EID: 0034711678     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.3.235     Document Type: Article

References (18)

1. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density protein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
2. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 1999;284:757-760.
3. Ricote M, Li AC, Willson TW, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
4. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
5. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR-γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-γ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546-551.
6. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
7. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
8. Patel SS, Thiagarajan R, Willerson JT, Yeh ETH. Inhibition of α4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in apoE-deficient mice. Circulation. 1998;97:75-81.
9. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997;89:2429-2442.
10. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83: 813-819.
11. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, Mizuno K, Fujita T, Tsukamoto K, Watanabe T. Thiazolidinediones down-regulate plasminogen activator inhibitor type-1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun. 1999;258:431-435.
12. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402.
13. Bishop-Bailey D, Hla TJ. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxydelta 12, 14-prostaglandin J2. J Biol Chem. 1999;274:17042-17048.
14. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83: 813-819.
15. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131.
16. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549-1558.
17. Law RE, Meehan WP, Xi XP, Graf C, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest. 1996;98:1897-1905.
18. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.